Found 1368 clinical trials
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
The purpose of the study is to characterize the pharmacokinetic (PK) profile of cetrelimab administered intravenous (IV) or subcutaneous (SC) in chronic hepatitis B (CHB) participants.
- 0 views
- 17 Jun, 2022
- 8 locations
Characterization of the Relationship Between the Human Mesolimbic Reward System and Immune Functioning
modulation of mesolimbic reward system, and the consecutive assesment of immune response to Hepatitis B vaccination.
- 4 views
- 25 Mar, 2022
- 1 location
Combination Treatment of NAs and Peg IFN -2b for Hepatitis B Related Compensatory Cirrhosis Patients
The study aims to demonstrate that whether treatment of nucleoside acidanalogues (NAs) plus pegylated interferon (Peg IFN) -2b for those NAs treated, low level of HBsAg, hepatitis B related
- 0 views
- 23 Jan, 2021
- 1 location
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV
- 0 views
- 24 Nov, 2021
- 1 location
Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
To date, antiviral treatment is not recommended for chronic hepatitis B patients with a normal ALT level and low viremia. The strategy is to closely monitor the patients. However, evidence
- 0 views
- 23 Mar, 2022
- 1 location
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides
Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of
- 0 views
- 21 Feb, 2022
- 10 locations
Liver Test Study of Using JKB-122 in HCV-Positive Patients
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have
- 32 views
- 07 Nov, 2020
- 5 locations
Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy
Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity.Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related
- 47 views
- 17 Mar, 2022
- 1 location
Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
This is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety of ASC42 in
- 0 views
- 22 Mar, 2022
- 1 location
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)
period, in patients with chronic Hepatitis D Virusinfection. Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week
- 0 views
- 22 Mar, 2022
- 1 location